PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Overview of vaccines • Understanding Meningococcal disease • Causes of meningococcal diseases • Signs and symptoms • Epidemiology • Vaccine approval process PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by composition • Mono vaccines • Combination vaccines PART 08: Geographical segmentation • Global meningococcal vaccines market by geographical segmentation 2015-2020 • Meningococcal vaccines market in Americas • Meningococcal vaccines market in US • Meningococcal vaccines market in the Brazil • Meningococcal vaccines market in EMEA • Meningococcal vaccines market in Europe • Meningococcal vaccines market in APAC • Meningococcal vaccines market in Australia PART 09: Market drivers • Increase in awareness about vaccination and immunization programs • Designated as a traveler's vaccine • Inclusion in national immunization schedule • Threat of bioterrorism • Additional age group approval PART 10: Impact of drivers PART 11: Market challenges • Vaccine storage and handling issues • High cost associated with vaccine development • Stringent regulations • Emergence of local players • Adverse effects PART 12: Impact of drivers and challenges PART 13: Market trends • Availability of combination vaccines • Increase in strategic alliances and M&A • Focus on emerging markets • Public-private initiatives PART 14: Vendor landscape • Competitive scenario • Market share analysis 2015 • Sanofi • GlaxoSmithKline (GSK) • Pfizer • Other prominent vendors PART 15: Appendix • List of abbreviations PART 16: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for meningococcal vaccines Exhibit 03: Distribution of meningococcal bacterial strains Exhibit 04: Distribution of meningococcal bacterial strains in US Exhibit 05: Distribution of meningococcal bacterial strains UK Exhibit 06: Different type of bacterial causes of meningitis Exhibit 07: Requirements for a BLA submission Exhibit 08: Different types of development necessary to reach vaccine licensing stage Exhibit 09: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion Exhibit 10: Regulatory testing of licensed vaccines Exhibit 11: Pediatric/VFC meningococcal vaccine price list 2015 Exhibit 12: Price of adult meningococcal vaccine 2015 Exhibit 13: Global meningococcal vaccines market 2015-2020 ($ billions) Exhibit 14: Five forces analysis Exhibit 15: Global meningococcal vaccines market segmentation by composition Exhibit 16: Global meningococcal vaccines market by composition 2015 Exhibit 17: Global meningococcal vaccines market by geography 2015 Exhibit 18: Global meningococcal vaccines market revenue by geography 2015-2020 ($ millions) Exhibit 19: Percentage share of meningococcal vaccines market by geography 2015-2020 Exhibit 20: Global meningococcal vaccines market: YoY revenue and growth based on geography 2015-2020 ($ millions) Exhibit 21: Meningococcal vaccines market in Americas 2015-2020 ($ billions) Exhibit 22: Meningococcal vaccines market in America by country 2015 Exhibit 23: Meningococcal vaccines market in US 2015-2020 ($ billions) Exhibit 24: Meningococcal vaccines market in Brazil 2015-2020 ($ millions) Exhibit 25: Meningococcal vaccines market in EMEA 2015-2020 ($ millions) Exhibit 26: Meningococcal vaccines market in EMEA by country 2015 Exhibit 27: Meningococcal vaccines market in Europe 2015-2020 ($ millions) Exhibit 28: Meningococcal vaccines market in APAC 2015-2020 ($ millions) Exhibit 29: Meningococcal vaccines market in APAC by country 2015 Exhibit 30: Meningococcal vaccines market in Australia 2015-2020 ($ millions) Exhibit 31: Impact of drivers Exhibit 32: A typical cold chain process Exhibit 33: Impact of drivers and challenges Exhibit 34: Overview of major vaccine related acquisitions (2005-2012) Exhibit 35: Market share analysis of global meningococcal vaccines market 2015 Exhibit 36: Sanofi: YoY revenue growth of Meningitis/Pneumonia vaccines 2013-2015 ($ millions) Exhibit 37: Geographical segmentation of meningitis/pneumococcal vaccines by revenue 2015 Exhibit 38: Sanofi: YoY revenue growth of Menactra 2013-2015 ($ millions) Exhibit 39: Geographical segmentation of Menomune by revenue 2015 Exhibit 40: Key takeaways Exhibit 41: Geographical segmentation of Bexsero by revenue 2015 Exhibit 42: Geographical segmentation of Menveo by revenue 2015 Exhibit 43: Key takeaways Exhibit 44: Key takeaways

GSK, Sanofi, Pfizer, Beijing Minhai Biotechnology, Bio Med, Hualan Biological Engineering, Imunoloski Zavod, JN International Medical, Nuron Biotech, Serum Institute of India, Vacunas Finlay, Merck, GlycoVaxyn, Baxter.